Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. Methods: BRAF V600E and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. Results: BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall interaction

Original languageEnglish (US)
Article numberdjv186
JournalJournal of the National Cancer Institute
Volume107
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Mutation Rate
Colonic Neoplasms
Survival
Neoplasms
Adjuvant Chemotherapy
Proportional Hazards Models
Disease-Free Survival
Recurrence
Mutation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{bae82e04f3b0461a9aaba8eaa3d96ea8,
title = "Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients",
abstract = "Background: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. Methods: BRAF V600E and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. Results: BRAF mutation frequency in tumors from whites (13.9{\%}) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1{\%}). KRAS/BRAF wild-type tumors were most common among Asians (66.7{\%}) (P overall interaction",
author = "Yoon, {Harry H} and Shi, {Qian D} and Alberts, {Steven Robert} and Goldberg, {Richard M.} and Thibodeau, {Stephen N} and Sargent, {Daniel J.} and Sinicrope, {Frank A}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/jnci/djv186",
language = "English (US)",
volume = "107",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients

AU - Yoon, Harry H

AU - Shi, Qian D

AU - Alberts, Steven Robert

AU - Goldberg, Richard M.

AU - Thibodeau, Stephen N

AU - Sargent, Daniel J.

AU - Sinicrope, Frank A

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. Methods: BRAF V600E and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. Results: BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall interaction

AB - Background: It is unknown if, after controlling for clinicopathologic variables and treatment, racial disparities in colon cancer outcomes persist. Molecular marker analysis in North American patients comparing Asians with other races has not been reported. Methods: BRAF V600E and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). Race categories included Asian, black, or white. Cox models were used to estimate disease-free survival (DFS) and time to recurrence (TTR). All statistical tests were two-sided. Results: BRAF mutation frequency in tumors from whites (13.9%) was twice that of tumors from Asians or blacks. KRAS mutation rates were highest in tumors from blacks (44.1%). KRAS/BRAF wild-type tumors were most common among Asians (66.7%) (P overall interaction

UR - http://www.scopus.com/inward/record.url?scp=84944677581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944677581&partnerID=8YFLogxK

U2 - 10.1093/jnci/djv186

DO - 10.1093/jnci/djv186

M3 - Article

C2 - 26160882

AN - SCOPUS:84944677581

VL - 107

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

M1 - djv186

ER -